Clinical trial designs for more rapid proof-of-principle and approval

Cancer Drug Design and Discovery

Volumn , Issue , 2008, Pages 53-87

  Borad, Mitesh J ^a   Von Hoff, Daniel D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871944987     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369448-5.50006-9     Document Type: Chapter

References (138)

1. Amadori S., Suciu S., Stasi R., et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005, 19:1768-1773.
2. Babb J., Rogatko A., Zacks S. Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 1998, 17:1103-1120.
3. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 1996, 334:488-493.
4. Bernards R. Exploring the uses of RNAi - gene knockdown and the Nobel Prize. N. Engl. J. Med. 2006, 355:2391-2393.
5. Bhargava P., Marshall J.L., Dahut W., et al. A Phase I and pharmacokinetic study of squalamine, a novel anti-angiogenic agent, in patients with advanced cancers. Clin. Cancer Res. 2001, 7:3912-3919.
6. Bonetti A., Zaninelli M., Leone R., et al. Use of the ratio of time to progression following first- and secondline therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann. Oncol. 2001, 12:187-191.
7. Booth B., Glassman R., Ma P. Oncology's trials. Nat. Rev. Drug Discov. 2003, 2:609-610.
8. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
9. Calvo E., Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 2006, 24:2158-2163.
10. Carter S.K., Selawry O., Slavik M. Phase I clinical trials. Natl Cancer Inst. Monogr. 1977, 45:75-80.
11. Chen T.T. Optimal three-stage designs for Phase II cancer clinical trials. Stat. Med. 1997, 16:2701-2711.
12. Chen T.T., Chute J.P., Feigal E. A model to select chemotherapy regimens for Phase III trials for extensive-stage small cell lung cancer. J. Natl Cancer Inst. 2000, 92:1601-1607.
13. Cheng J.D., Babb J.S., Langer C., et al. Individualized patient dosing in Phase I clinical trials: the role of escalation with overdose control in PNU-214936. J. Clin. Oncol. 2004, 22:602-609.
14. Choi H., Charnsangavej C., de Castro Faria S., et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol. 2004, 183:1619-1628.
15. Collins J.M., Zaharko D.S., Dedrick R.L., Chabner B.A. Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat Rep. 1986, 70:73-80.
16. Collins J.M., Grieshaber C.K., Chabner B.A. Pharmacologically guided Phase I clinical trials based upon preclinical drug development. J. Natl Cancer Inst. 1990, 82:1321-1326.
17. Cunningham E.T., da Silva L., Harrison E.M. Accelerated drug development through combined phase 2/3 clinical trial design. Arch. Ophthalmol. 2004, 122:1043-1044.
18. Dagher R., Johnson J., Williams G., et al. Accelerated approval of oncology products: a decade of experience. J. Natl Cancer Inst. 2004, 96:1500-1509.
19. Dees E.C., Whitfield L.R., Grove W.R., et al. A Phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin. Cancer Res. 2000, 6:3885-3894.
20. Dittrich C., Greim G., Borner M., et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur. J. Cancer 2002, 38:1072-1080.
21. Donawho C.K., Luo Y., Penning T.D., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13(9):2728-2737.
22. Dowlati A., Haaga J., Remick S.C., et al. Sequential tumor biopsies in early phase clinical trials of anti-cancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 2001, 7:2971-2976.
23. Dowsett M., Smith I.E., Ebbs S.R., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 2005, 11:S951-S958.
24. Dowsett M., Smith I.E., Ebbs S.R., et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. 2006, 12:S1024-S1030.
25. Dziewanowska Z., Zhang J., Sun S., et al. Components of metabolic syndrome correlate with longer survival in NSCLC in bexarotene-treated patients with high hypertriglyceridemia in SPIRIT I and II trials: a retrospective analysis. Proceedings of the 2006 ASCO Annual Meeting 2006, Abstract 7137.
26. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer. 2006, 95:581-586.
27. Eisenhauer E.A., O'Dwyer P.J., Christian M., Humphrey J.S. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 2000, 18:684-692.
28. Estey E.H., Thall P.F. New designs for phase 2 clinical trials. Blood 2003, 102:442-448.
29. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 2005, 23:4117-4126.
30. Fleming T.R. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 1982, 38:143-151.
31. Fleming T.R., DeMets D.L. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 1996, 125:605-613.
32. Fossa S.D., Mickisch G.H., de Mulder P.H., et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004, 101:533-540.
33. Fox E., Curt G.A., Balis F.M. Clinical trial design for target-based therapy. Oncologist 2002, 7:401-409.
34. Freemantle N., Calvert M., Wood J., et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? J. Am. Med. Assoc. 2003, 289:2554-2559.
35. Freidlin B., Simon R. Evaluation of randomized discontinuation design. J. Clin. Oncol. 2005, 23:5094-5098.
36. Freidlin B., Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res. 2005, 11:7872-7878.
37. Freidlin B., Breathnach O.S., Johnson B.E. A model to select regimens for Phase III trials for patients with advanced-stage non-small cell lung cancer. Clin. Cancer Res. 2003, 9:917-922.
38. Freireich E.J. The investigational new drug application - who benefits? Nat. Clin. Pract. Oncol. 2006, 3:62-63.
39. Frohna P., Lu J., Eppler S., et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J. Clin. Pharmacol. 2006, 46:282-290.
40. Fukuoka M., Yano S., Giaccone G., et al. Multiinstitutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) (corrected). J. Clin. Oncol. 2003, 21:2237-2246.
41. Gadgeel S.M., Wozniak A., Boinpally R.R., et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res. 2005, 11:6233-6239.
42. Gehan E.A., Tefft M.C. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J. Natl Cancer Inst. 2000, 92:179-181.
43. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
44. Glynn R.J., Rosner B. Methods to evaluate risks for composite end points and their individual components. J. Clin. Epidemiol. 2004, 57:113-122.
45. Goetz M.P., Toft D., Reid J., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23:1078-1087.
46. Goffin J., Baral S., Tu D., et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin. Cancer Res. 2005, 11:5928-5934.
47. Goh B.C., Ratain M.J., Bertucci D., et al. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J. Clin. Oncol. 2001, 19:1476-1484.
48. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
49. Harland S.J., Newell D.R., Siddik Z.H., et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984, 44:1693-1697.
50. Hayes D.F., Cristofanilli M., Budd G.T., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12:4218-4224.
51. Hayes L. Unequal access to midwifery care: a continuing problem? J. Adv. Nurs. 1995, 21:702-707.
52. Hede K. Patient group seeks overhaul of FDA clinical trial system in court. J. Natl Cancer Inst. 2006, 98:1268-1270.
53. Heinicke T., Wardelmann E., Sauerbruch T., et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res. 2005, 25:4591-4594.
54. Herson J., Carter S.K. Calibrated Phase II clinical trials in oncology. Stat. Med. 1986, 5:441-447.
55. Holz F.G., Miller D.W. Pharmacological therapy for age-related macular degeneration. Current developments and perspectives. Ophthalmologie 2003, 100:97-103.
56. Hughes M.D., Daniels M.J., Fischl M.A., et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. Aids 1998, 12:1823-1832.
57. InnoMed Within InnoMed an improvement in clinical research with regards to efficacy and patient recruitment 2004. http://ec.europa.eu/research/fp6/p1/innovative-medicines/pdf/vision_en.p df.
58. Inoue L.Y., Thall P.F., Berry D.A. Seamlessly expanding a randomized Phase II trial to Phase III. Biometrics 2002, 58:823-831.
59. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2004, 22:2184-2191.
60. Johnson J.R., Williams G., Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 2003, 21:1404-1411.
61. Jordan S.D., Poole C.J., Archer V.R., et al. A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens. Cancer Chemother. Pharmacol. 2003, 52:113-118.
62. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 2005, 11:2785-2808.
63. Kelloff G.J., Lippman S.M., Dannenberg A.J., et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin. Cancer Res. 2006, 12:3661-3697.
64. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004, 3:711-715.
65. Korn E.L., Arbuck S.G., Pluda J.M., et al. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 2001, 19:265-272.
66. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006, 107:2678-2687.
67. Lavin P.T. An alternative model for the evaluation of anti-tumor activity. Cancer Clin. Trials 1981, 4:451-457.
68. Lee J.J., Feng L. Randomized Phase II designs in cancer clinical trials: current status and future directions. J. Clin. Oncol. 2005, 23:4450-4457.
69. Lim N., Lara P.N., Lau D.H., et al. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest 2003, 21:7-13.
70. Maitland M.L., Moshier K., Imperial J., et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. Proceedings of the 2006 ASCO Annual Meeting 2006, Abstract 2035.
71. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Stat. Med. 2005, 24:329-339.
72. Maker A.V., Yang J.C., Sherry R.M., et al. Intra patient dose escalation of anti-CTLA 4 antibody in patients with metastatic melanoma. J. Immunother. 2006, 29:455-463.
73. Measday V., Baetz K., Guzzo J., et al. Systematic yeast synthetic lethal and synthetic dosage lethal screens identify genes required for chromosome segregation. Proc. Natl Acad. Sci USA 2005, 102:13,956-13,961.
74. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat. Med. 1995, 14:911-922. discussion 923.
75. Montori V.M., Permanyer-Miralda G., Ferreira-Gonzalez I., et al. Validity of composite end points in clinical trials. Br. Med. J. 2005, 330:594-596.
76. Moreno J.G., O'Hara S.M., Gross S., et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001, 58:386-392.
77. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. J. Am. Med. Assoc. 2004, 291:2720-2726.
78. Omura G.A. Modified Fibonacci search. J. Clin. Oncol. 2003, 21:3177.
79. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990, 46:33-48.
80. O'Shaughnessy J.A., Wittes R.E., Burke G., et al. Commentary concerning demonstration of safety and efficacy of investigational anti-cancer agents in clinical trials. J. Clin. Oncol. 1991, 9:2225-2232.
81. Pazdur R. Response rates, survival, and chemotherapy trials. J. Natl Cancer Inst. 2000, 92:1552-1553.
82. Piantadosi S., Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Stat. Med. 1996, 15:1605-1618.
83. Plummer R., Ghielmini M., Calvert P., et al. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin. Cancer Res. 2002, 8:2788-2797.
84. Racila E., Euhus D., Weiss A.J., et al. Detection and characterization of carcinoma cells in the blood. Proc. Natl Acad. Sci. USA 1998, 95:4589-4594.
85. Ratain M.J. Drug combinations: dangerous liaisons or great expectations? Ann. Oncol. 1999, 10:375-376.
86. Ratain M.J. Phase II oncology trials: let's be positive. Clin. Cancer Res. 2005, 11:5661-5662.
87. Ratain M.J. From biomarkers to clinical utility. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2006, Vol. 4:75. Elsevier, Prague, Czech Republic.
88. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:2505-2512.
89. Rinaldi D.A., Burris H.A., Dorr F.A., et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 1995, 13:2842-2850.
90. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
91. Roberts T.G., Lynch T.J., Chabner B.A. The Phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J. Clin. Oncol. 2003, 21:3683-3695.
92. Rogatko A., Babb J.S., Tighiouart M., et al. New paradigm in dose-finding trials: patient-specific dosing and beyond Phase I. Clin. Cancer Res. 2005, 11:5342-5346.
93. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 2003, 21:3150-3157.
94. Rosner G.L., Stadler W., Ratain M.J. Randomized discontinuation design: application to cytostatic anti-neoplastic agents. J. Clin. Oncol. 2002, 20:4478-4484.
95. Ross H., Bonomi P., Langer C., et al. Effect of gender on outcome in two randomized Phase III trials of paclitaxel poliglumex (PPX) in chemonaive patients with advanced NSCLC and poor performance status (PS2). Proceedings of the 2006 ASCO Annual Meeting 2006, Abstract 7039.
96. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by {18F} fluorodeoxyglucose positron emission tomography. J. Clin. Oncol. 2006, 24:5366-5372.
97. Rowinsky E.K., Rizzo J., Ochoa L., et al. A Phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 2003, 21:148-157.
98. Royce M.E., Hoff P.M., Dumas P., et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J. Clin. Oncol. 2001, 19:1493-1500.
99. Rubinstein L.V., Korn E.L., Freidlin B., et al. Design issues of randomized Phase II trials and a proposal for Phase II screening trials. J. Clin. Oncol. 2005, 23:7199-7206.
100. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23:5474-5483.
101. Rustin G.J., Bast R.C., Kelloff G.J., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 2004, 10:3919-3926.
102. Sargent D.J., Conley B.A., Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 2005, 23:2020-2027.
103. Schaid D.J., Ingle J.N., Wieand S., Ahmann D.L. A design for Phase II testing of anti-cancer agents within a Phase III clinical trial. Control Clin. Trials 1988, 9:107-118.
104. Schellens J.H., Planting A.S., van Zandwijk N., et al. Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with non-small cell lung cancer. Br. J. Cancer 2003, 88:814-821.
105. Schiller J.H. Clinical trial design issues in the era of targeted therapies. Clin. Cancer Res. 2004, 10:S4281-S4282.
106. Shaked Y., Bertolini F., Emmenegger U., et al. On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J. Clin. Oncol. 2006, 24:4040. author reply 4040-4041.
107. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 2005, 23:7332-7341.
108. Simon R. A checklist for evaluating reports of expression profi ling for treatment selection. Clin. Adv. Hematol. Oncol. 2006, 4:219-224.
109. Simon R. Moving from correlative studies to predictive medicine: how to include biomarkers in clinical trials. The First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment 2006, 100. AACR, Chicago.
110. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 2004, 10:6759-6763.
111. Simon R., Wittes R.E., Ellenberg S.S. Randomized Phase II clinical trials. Cancer Treat Rep. 1985, 69:1375-1381.
112. Simon R., Freidlin B., Rubinstein L., et al. Accelerated titration designs for Phase I clinical trials in oncology. J. Natl Cancer Inst. 1997, 89:1138-1147.
113. Simon R.M., Steinberg S.M., Hamilton M., et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 2001, 19:1848-1854.
114. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 2005, 23:5108-5116.
115. Stadler W.M., Rosner G., Small E., et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative anti-angiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J. Clin. Oncol. 2005, 23:3726-3732.
116. Storer B.E. Design and analysis of Phase I clinical trials. Biometrics 1989, 45:925-937.
117. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
118. Syed S., Takimoto C., Hidalgo M., et al. A Phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and anti-tumor properties. Clin. Cancer Res. 2004, 10:6512-6521.
119. Takimoto C.H. Phase zero clinical trials in oncology; a new paradigm for early drug development?. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2006, Vol. 4:8. Elsevier, Prague, no. 12.
120. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 2004, 351:2049-2057.
121. Temple R.J. Enrichment designs: efficiency in development of cancer treatments. J. Clin. Oncol. 2005, 23:4838-4839.
122. Temple R. How FDA currently makes decisions on clinical studies. Clin. Trials. 2005, 2:276-281. discussion 364-378.
123. Thall P.F., Simon R., Ellenberg S.S., Shrager R. Optimal two-stage designs for clinical trials with binary response. Stat. Med. 1988, 7:571-579.
124. Tighiouart M., Rogatko A., Babb J.S. Flexible Bayesian methods for cancer Phase I clinical trials. Dose escalation with overdose control. Stat. Med. 2005, 24:2183-2196.
125. Trunet P.F., Mueller P., Bhatnagar A.S., et al. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J. Clin. Endocrinol. Metab. 1993, 77:319-323.
126. Twombly R. FDA Oncology Committee debates Iressa's status following negative trial results. J. Natl Cancer Inst. 2005, 97:473.
127. Undevia S.D., Vogelzang N.J., Mauer A.M., et al. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs 2004, 22:449-458.
128. USFDA FDA proposes rules overhaul to expand availability of experimental drugs. FDA News For Immediate Release 2006, USDHHS, Washington, DC.
129. Von Hoff D.D. There are no bad anti-cancer agents, only bad clinical trial designs - Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 1998, 4:1079-1086.
130. von Moltke L.L., Greenblatt D.J., Schmider J., et al. In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 1998, 55:113-122.
131. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 1999, 17:658-667.
132. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 2003, 21:2651-2657.
133. Wieand H.S. Randomized Phase II trials: what does randomization gain? J. Clin. Oncol. 2005, 23:1794-1795.
134. Williams G., Pazdur R., Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J. Biopharm. Stat. 2004, 14:5-21.
135. Woodward W.A., Huang E.H., McNeese M.D., et al. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicinbased chemotherapy. Cancer 2006, 107:2662-2668.
136. Woosley R.L., Cossman J. Drug development and the FDA's Critical Path Initiative. Clin. Pharmacol. Ther. 2007, 81:129-133.
137. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
138. Zujewski J., Horak I.D., Bol C.J., et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 2000, 18:927-941.